Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms

被引：0

作者：

Gurler, Fatih ^{[1
,8
]}

Esen, Selin Akturk ^{[2
]}

Inci, Bediz Kurt ^{[3
]}

Sutcuoglu, Osman ^{[4
]}

Ucar, Gokhan ^{[2
]}

Akdogan, Orhun ^{[5
]}

Uncu, Dogan ^{[2
]}

Turhan, Nesrin ^{[6
]}

Akyurek, Nalan ^{[7
]}

Ozdemir, Nuriye ^{[4
]}

Ozet, Ahmet ^{[4
]}

Yazici, Ozan ^{[4
]}

机构：

[1] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye

[2] Univ Hlth Sci, Ankara City Hosp, Dept Med Oncol, Ankara, Turkiye

[3] Aksaray Training & Res Hosp, Dept Med Oncol, Aksaray, Turkiye

[4] Gazi Univ, Sch Med, Dept Med Oncol, Ankara, Turkiye

[5] Yenimahalle Training & Res Hosp, Dept Internal Med, Ankara, Turkiye

[6] Univ Hlth Sci, Ankara City Hosp, Dept Pathol, Ankara, Turkiye

[7] Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkiye

[8] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Yenimahalle Ankara, Turkiye

来源：

CANCER INVESTIGATION | 2024年 / 42卷 / 02期

关键词：

PD-L1; LAG-3; TIM-3; OX40L; MSI; TUMOR-INFILTRATING LYMPHOCYTES; MICROSATELLITE INSTABILITY; PHASE-II; CANCER; PATHWAYS; EFFICACY; PROTEIN; SAFETY; CD223;

D O I：

10.1080/07357907.2024.2330102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor. A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.

引用

页码：141 / 154

页数：14

共 50 条

[41] 脊柱结核中PD-L1、LAG-3的表达及临床病理相关性分析 [J].

王新 ;

王天香 ;

耿艳华 ;

施佳 ;

梁木凤 ;

周美玲 ;

吴千叶 .

浙江临床医学, 2023, 25 (04) :590-592

[42] Expression status of PD-L1 and B7-H3 in mesothelioma [J].

Matsumura, Eiji ;

Kajino, Kazunori ;

Abe, Masaaki ;

Ohtsuji, Naomi ;

Saeki, Harumi ;

Hlaing, May Thinzar ;

Hino, Okio .

PATHOLOGY INTERNATIONAL, 2020, 70 (12) :999-1008

[43] Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and GermlineBRCAStatus [J].

Whitehair, Rachel ;

Peres, Lauren C. ;

Mills, Anne M. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (06) :558-566

[44] PD-L1 Expression and Immune Cell In fi ltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity [J].

Ferrata, Martina ;

Schad, Arno ;

Zimmer, Stefanie ;

Musholt, Thomas J. ;

Bahr, Katharina ;

Kuenzel, Julian ;

Becker, Sven ;

Springer, Erik ;

Roth, Wilfried ;

Weber, Matthias M. ;

Fottner, Christian .

FRONTIERS IN ONCOLOGY, 2019, 9

[45] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) [J].

Andrea De Giglio ;

Alessandro Di Federico ;

Giacomo Nuvola ;

Chiara Deiana ;

Francesco Gelsomino .

Current Oncology Reports, 2021, 23

[46] Blood Clot Scaffold Loaded with Liposome Vaccine and siRNAs Targeting PD-L1 and TIM-3 for Effective DC Activation and Cancer Immunotherapy [J].

Chen, Yitong ;

Zhang, Yue ;

Wang, Beilei ;

Fan, Qin ;

Yang, Qianyu ;

Xu, Jialu ;

Dai, Huaxing ;

Xu, Fang ;

Wang, Chao .

ACS NANO, 2023, 17 (01) :760-774

[47] Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma [J].

Stuehler, Viktoria ;

Alemi, Bilal ;

Rausch, Steffen ;

Stenzl, Arnulf ;

Schwab, Matthias ;

Schaeffeler, Elke ;

Bedke, Jens .

WORLD JOURNAL OF UROLOGY, 2024, 42 (01)

[48] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) [J].

De Giglio, Andrea ;

Di Federico, Alessandro ;

Nuvola, Giacomo ;

Deiana, Chiara ;

Gelsomino, Francesco .

CURRENT ONCOLOGY REPORTS, 2021, 23 (11)

[49] Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis [J].

Guo, Mengzhou ;

Yuan, Feifei ;

Qi, Feng ;

Sun, Jialei ;

Rao, Qianwen ;

Zhao, Zhiying ;

Huang, Peixin ;

Fang, Tingting ;

Yang, Biwei ;

Xia, Jinglin .

JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)

[50] Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis [J].

Mengzhou Guo ;

Feifei Yuan ;

Feng Qi ;

Jialei Sun ;

Qianwen Rao ;

Zhiying Zhao ;

Peixin Huang ;

Tingting Fang ;

Biwei Yang ;

Jinglin Xia .

Journal of Translational Medicine, 18

← 1 2 3 4 5 →